Allos Therapeutics announced the presentation of further data from its Phase 2b study of Folotyn (pralatrexate injection) relative to Tarceva (erlotinib, from Genentech) in patients with Stage IIIB/IV ...

FOLOTYN® (pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009 FOLOTYN net sales were approximately $50 million in 2011 ...

Investigator-sponsored preclinical in vivo research showed potential synergy of FOLOTYN® (pralatrexate injection), approved for single therapy of relapsed or refractory peripheral T-cell lymphoma ...

Allos is currently focused on the development and commercialization of FOLOTYN ® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S ...

BEIJING, Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and ...

Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN ® (pralatrexate injection) at the 58th Annual Meeting of the American Society ...

FOLOTYN (pralatrexate) 20mg/mL, 40mg/2mL injection by Allos Therapeutics The FDA has approved Folotyn (pralatrexate injection, from Allos Therapeutics), a folate analog, as a single agent for the ...

Spectrum Pharmaceuticals (NASDAQ: SPPI - News) and Allos Therapeutics, Inc. (NASDAQ: ALTH - News) today announced that they have signed a definitive agreement under which Spectrum will acquire all of ...

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in ...